Samsung Bioepis Snags Second EU Denosumab Biosimilar – But More Are On The Way
Rivals To Prolia And Xgeva Receive Endorsement From EMA’s CHMP
Samsung Bioepis may be only the second company to obtain an EMA positive opinion for a denosumab biosimilar, but plenty more rivals are on the way with filings of their own.
